Delisting riskPopularity #4,593
GOVX · NASDAQ · Biotechnology

GeoVax Labs (GOVX)

Clinical developer of an mpox/smallpox vaccine and gene-directed therapy for head-and-neck cancer.

$0.3850
vs last close+0.02 (+5.97%)
  1. GeoVax Labs Revenue Doubles in Q2

    The Motley Fool